Overall market sentiment has been neutral on BioCryst Pharmaceuticals Inc (BCRX) stock lately. BCRX receives a Neutral rating from InvestorsObserver Stock Sentiment Indicator.
BioCryst Pharmaceuticals Inc has a Neutral sentiment reading. Find out what this means for you and get the rest of the rankings on BCRX!
When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment.
Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive.
InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend.
Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .
What's Happening With BCRX Stock Today?
BioCryst Pharmaceuticals Inc (BCRX) stock is trading at $7.36 as of 2:12 PM on Monday, Jan 8, an increase of $1.26, or 20.77% from the previous closing price of $6.09. The stock has traded between $6.12 and $7.60 so far today. Volume today is elevated. So far 8,014,688 shares have traded compared to average volume of 4,126,031 shares.
To screen for more stocks like BioCryst Pharmaceuticals Inc click here.
More About BioCryst Pharmaceuticals Inc
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, with the aim of blocking key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
Click Here to get the full Stock Report for BioCryst Pharmaceuticals Inc stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
